U. J. Alexander BioNTech (NASDAQ:BNTX) was already starting to gain some recognition for its pioneering work in mRNA technology when it signed an agreement with Pfizer (PFE) to develop a mRNA-based vaccine to prevent the flu in 2018. However, few knew at the time that the relationship would pave the way for another collaboration that would go on to produce the highest-selling pharmaceutical product in a single year, with $36.8 billion in 2021 sales, the COVID-19 vaccine. Pfizer describes how it and BioNTech ...

BioNTech SE (NASDAQ:BNTX) Q3 2023 Earnings Call Transcript November 8, 2023 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CFO Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Yaron Werber - TD Cowen Jessica Fye - JPMorgan Bill Maughan - Canaccord Genuity Simon Baker - Redb ...

BA.2.86 remains low worldwide Growing dominance of the XBB-descendent EG.5.1 XBB.1.5-adapted monovalent vaccine elicits potent neutralization against various sublineages: XBB.1.5, EG.5.1, BA.2.86, XBB.1.16 and XBB.2.3 1. Partnered with Pfizer. 2.COMIRNATY approved for prevention of COVID-19 as a single dose for individuals 5 years of age and older and as a 3-dose series in individuals 6 months through 4 years of age. 3. COMIRNATY may be administered as a booster in people aged 12 years and older who have re ...

| --- | --- | --- | --- | |-----------------------------------------|-------|--------------------------------------|---------------------| | (in millions €) Assets | Note | September 30, \n2023 (unaudited) | December 31, \n2022 | | Non-current assets | | | | | Intangible assets | 5, 7 | 665.5 | 158.5 | | Goodwill | 5 | 365.6 | 61.2 | | Property, plant and equipment | | 728.9 | 609.2 | | Right-of-use assets | | 197.0 | 211.9 | | Other financial assets | 8 | 1,292.7 | 80.2 | | Other non-financial assets | | 0 ...

BioNTech SE (NASDAQ:BNTX) Q2 2023 Earnings Conference Call August 7, 2023 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CFO Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Brendan Smith - TD Cowen Terence Flynn - Morgan Stanley Bill Maughan - Canaccord Simon Baker - Redbu ...

Quarterly Report of BioNTech SE for the Three And Six Months Ended June 30, 2023 Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Changes in Stockholders' Equity 4 2 Basis of Preparation, Significant Accounting Policies and further Accounting Topics 6 6 Intangible Assets 12 10 Share-Based Payments 15 Operating and Financial Review and Prospects The accompanying notes form an integral part of these interim consolidated financial statements. 1 2 3 4 Th ...

analogs to trastuzumab, deruxtecan and trastuzumab emtansin, respectively. In red monkey and human plasma, DB-1303 demonstrated high drug to antibody ratio and outstanding plasma stability. Two points to that. So first is actually the volumes, while we're not disclosing volumes in the first quarter, we were shipping to quite a broad range of countries in the first quarter, over 70 countries we mentioned. There's still some carryover there to pandemic contracts. And so, as I mentioned in the prepared remarks ...

The increase of intangible assets by €158.9 million during the three months ended March 31, 2023 is mainly due to licenses acquired that meet the definition of identifiable assets in the amount of €158.0 million in connection with the License and Collaboration Agreements entered into between us and Duality Biologics (Suzhou) Co. Ltd., Shanghai, China, in March 2023. Set out below is an overview of financial assets, other than cash and cash equivalents, held as of March 31, 2023 and December Derivatives not ...

BioNTech SE (NASDAQ:BNTX) Q4 2022 Results Conference Call March 27, 2023 8:00 AM ET Company Participants Michael Horowicz - IR and Strategy Ugur Sahin - CEO and Co-Founder Özlem Türeci - Chief Medical Officer and Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Daina Graybosch - SVB Securities Matthew Harrison - Morgan Stanley Yaron Werber - Cowen Jessica Fye - JP Morgan Michael Horowicz Good morning and afternoon. Thank you ...

Title of each classTrading Symbol(s)Name of each exchange on which registered Ordinary shares, no par value, with a notional amount attributable to each ordinary share of €1* — The Nasdaq Stock Market LLC* FORM 20-F Securities registered or to be registered, pursuant to Section 12(b) of the Act Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Page GENERAL INFORMATION 3 CAUTIONARY STATEMENT RE ...